ES2983444T3 - Tratamiento de células madre en patologías endometriales - Google Patents
Tratamiento de células madre en patologías endometriales Download PDFInfo
- Publication number
- ES2983444T3 ES2983444T3 ES22150013T ES22150013T ES2983444T3 ES 2983444 T3 ES2983444 T3 ES 2983444T3 ES 22150013 T ES22150013 T ES 22150013T ES 22150013 T ES22150013 T ES 22150013T ES 2983444 T3 ES2983444 T3 ES 2983444T3
- Authority
- ES
- Spain
- Prior art keywords
- bmdscs
- subject
- endometrial
- isolated
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002357 endometrial effect Effects 0.000 title claims abstract description 84
- 230000007170 pathology Effects 0.000 title abstract description 11
- 238000002660 stem cell treatment Methods 0.000 title description 7
- 208000002777 Gynatresia Diseases 0.000 claims abstract description 49
- 210000000130 stem cell Anatomy 0.000 claims abstract description 38
- 206010051909 Endometrial atrophy Diseases 0.000 claims abstract description 29
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 26
- 238000011069 regeneration method Methods 0.000 claims abstract description 24
- 210000000685 uterine artery Anatomy 0.000 claims abstract description 24
- 230000008929 regeneration Effects 0.000 claims abstract description 23
- 102100040120 Prominin-1 Human genes 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 54
- 238000011282 treatment Methods 0.000 claims description 48
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 20
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 20
- 238000002617 apheresis Methods 0.000 claims description 13
- 238000002513 implantation Methods 0.000 claims description 13
- 210000002565 arteriole Anatomy 0.000 claims description 12
- 210000005259 peripheral blood Anatomy 0.000 claims description 10
- 239000011886 peripheral blood Substances 0.000 claims description 10
- 230000003054 hormonal effect Effects 0.000 claims description 9
- 208000037093 Menstruation Disturbances Diseases 0.000 claims description 7
- 201000000736 Amenorrhea Diseases 0.000 claims description 6
- 206010001928 Amenorrhoea Diseases 0.000 claims description 6
- 231100000540 amenorrhea Toxicity 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- 208000035175 Oligomenorrhea Diseases 0.000 claims description 5
- 206010030295 Oligomenorrhoea Diseases 0.000 claims description 5
- 206010021033 Hypomenorrhoea Diseases 0.000 claims description 4
- 230000032692 embryo implantation Effects 0.000 claims description 4
- 230000003836 peripheral circulation Effects 0.000 claims description 4
- 208000008899 Habitual abortion Diseases 0.000 claims description 3
- 230000001483 mobilizing effect Effects 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 31
- 208000028685 Asherman syndrome Diseases 0.000 description 47
- 210000004696 endometrium Anatomy 0.000 description 36
- 238000002657 hormone replacement therapy Methods 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000005906 menstruation Effects 0.000 description 10
- 210000001367 artery Anatomy 0.000 description 9
- 210000004204 blood vessel Anatomy 0.000 description 9
- 230000035935 pregnancy Effects 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 9
- 239000010410 layer Substances 0.000 description 8
- 230000002175 menstrual effect Effects 0.000 description 8
- 230000027758 ovulation cycle Effects 0.000 description 8
- 201000001389 adhesions of uterus Diseases 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 239000002346 layers by function Substances 0.000 description 7
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 230000001413 cellular effect Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 208000000995 spontaneous abortion Diseases 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 description 5
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000000754 myometrium Anatomy 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 206010036601 premature menopause Diseases 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- 206010000234 Abortion spontaneous Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 210000004504 adult stem cell Anatomy 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000035558 fertility Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 208000021267 infertility disease Diseases 0.000 description 4
- 208000015994 miscarriage Diseases 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 210000000603 stem cell niche Anatomy 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 102000052030 Aldehyde Dehydrogenase 1 Family Human genes 0.000 description 3
- 101710196131 Aldehyde dehydrogenase 1 Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 208000035002 Pregnancy of unknown location Diseases 0.000 description 3
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 3
- 206010041660 Splenomegaly Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 238000002659 cell therapy Methods 0.000 description 3
- 230000035606 childbirth Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 201000003511 ectopic pregnancy Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000010102 embolization Effects 0.000 description 3
- 230000000762 glandular Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000001361 intraarterial administration Methods 0.000 description 3
- WTFXARWRTYJXII-UHFFFAOYSA-N iron(2+);iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[Fe+2].[Fe+3].[Fe+3] WTFXARWRTYJXII-UHFFFAOYSA-N 0.000 description 3
- 201000010260 leiomyoma Diseases 0.000 description 3
- 229960004400 levonorgestrel Drugs 0.000 description 3
- 231100000544 menstrual irregularity Toxicity 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000009168 stem cell therapy Methods 0.000 description 3
- 238000009580 stem-cell therapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 208000006379 syphilis Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000007998 vessel formation Effects 0.000 description 3
- 108010005465 AC133 Antigen Proteins 0.000 description 2
- 102000005908 AC133 Antigen Human genes 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 101150017554 LGR5 gene Proteins 0.000 description 2
- 208000035752 Live birth Diseases 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001105 femoral artery Anatomy 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000004217 heart function Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000029849 luteinization Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 210000004967 non-hematopoietic stem cell Anatomy 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000013309 porous organic framework Substances 0.000 description 2
- 230000002980 postoperative effect Effects 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000001172 regenerating effect Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 210000001956 EPC Anatomy 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 1
- 101000738354 Homo sapiens CD9 antigen Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000002152 Splenic rupture Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 206010046764 Uterine atrophy Diseases 0.000 description 1
- 208000032095 Uterine synechiae Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 102000049842 cholesterol binding protein Human genes 0.000 description 1
- 108010011793 cholesterol binding protein Proteins 0.000 description 1
- 208000030373 chronic endometritis Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000002697 interventional radiology Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- DCYOBGZUOMKFPA-UHFFFAOYSA-N iron(2+);iron(3+);octadecacyanide Chemical compound [Fe+2].[Fe+2].[Fe+2].[Fe+3].[Fe+3].[Fe+3].[Fe+3].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] DCYOBGZUOMKFPA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000037211 monthly cycles Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000015124 ovarian disease Diseases 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000543 ovarian dysfunction Toxicity 0.000 description 1
- 230000011599 ovarian follicle development Effects 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229960003351 prussian blue Drugs 0.000 description 1
- 239000013225 prussian blue Substances 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 230000002784 sclerotic effect Effects 0.000 description 1
- 238000010187 selection method Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 231100001042 uterine atrophy Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thermotherapy And Cooling Therapy Devices (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462013121P | 2014-06-17 | 2014-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2983444T3 true ES2983444T3 (es) | 2024-10-23 |
Family
ID=54329860
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES22150013T Active ES2983444T3 (es) | 2014-06-17 | 2015-06-05 | Tratamiento de células madre en patologías endometriales |
| ES15781411T Active ES2736117T3 (es) | 2014-06-17 | 2015-06-05 | Tratamiento de células madre en patologías endometriales |
| ES19169309T Active ES2910306T3 (es) | 2014-06-17 | 2015-06-05 | Tratamiento de células madre en patologías endometriales |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES15781411T Active ES2736117T3 (es) | 2014-06-17 | 2015-06-05 | Tratamiento de células madre en patologías endometriales |
| ES19169309T Active ES2910306T3 (es) | 2014-06-17 | 2015-06-05 | Tratamiento de células madre en patologías endometriales |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US11129851B2 (OSRAM) |
| EP (3) | EP3158057B1 (OSRAM) |
| JP (2) | JP6920062B2 (OSRAM) |
| CN (2) | CN107073040A (OSRAM) |
| AU (1) | AU2015275798B2 (OSRAM) |
| BR (1) | BR112016029558A2 (OSRAM) |
| CA (1) | CA2952559C (OSRAM) |
| CY (2) | CY1122615T1 (OSRAM) |
| DK (2) | DK3158057T3 (OSRAM) |
| ES (3) | ES2983444T3 (OSRAM) |
| HR (3) | HRP20220419T1 (OSRAM) |
| HU (3) | HUE044823T2 (OSRAM) |
| LT (2) | LT3158057T (OSRAM) |
| MX (1) | MX377300B (OSRAM) |
| PL (3) | PL4012023T3 (OSRAM) |
| PT (2) | PT3569697T (OSRAM) |
| RS (3) | RS65719B1 (OSRAM) |
| RU (1) | RU2725006C2 (OSRAM) |
| SI (2) | SI3158057T1 (OSRAM) |
| SM (3) | SMT201900400T1 (OSRAM) |
| TR (1) | TR201910410T4 (OSRAM) |
| WO (1) | WO2015193737A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| EP3467124A1 (en) | 2012-06-06 | 2019-04-10 | Fundació Institut de Recerca Biomèdica IRB (Barcelona) | Method for the diagnosis, prognosis and treatment of lung cancer metastasis |
| US10119171B2 (en) | 2012-10-12 | 2018-11-06 | Inbiomotion S.L. | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis |
| ES2744244T3 (es) | 2012-10-12 | 2020-02-24 | Inbiomotion Sl | Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-MAF |
| EP3272880B1 (en) | 2013-03-15 | 2020-11-25 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Method for the diagnosis, prognosis and treatment of metastatic cancer |
| CA2952559C (en) | 2014-06-17 | 2023-01-24 | Igenomix S.L. | Stem cell therapy in endometrial pathologies |
| CA3028422A1 (en) * | 2016-06-23 | 2017-12-28 | Tithon Biotech, Inc. | Cells expressing parathyroid hormone 1 receptor and uses thereof |
| RU2699029C1 (ru) * | 2018-12-10 | 2019-09-03 | Частное образовательное учреждение дополнительного профессионального образования "Академия медицинского образования имени Федора Ивановича Иноземцева" (ЧОУ ДПО "Академия медицинского образования им. Ф.И. Иноземцева") | Способ использования мезенхимальных стволовых клеток для улучшения состояния рубца на матке |
| RU2741621C1 (ru) * | 2020-09-25 | 2021-01-28 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации | Способ лечения внутриматочных синехий |
| WO2023003130A1 (ko) | 2021-07-23 | 2023-01-26 | 차의과학대학교 산학협력단 | 분리된 미토콘드리아를 유효성분으로 포함하는 아셔만 증후군 예방 또는 치료용 약학 조성물 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR920700648A (ko) | 1989-05-05 | 1992-08-10 | 오닐 크리스토퍼 | 가임성 향상 |
| US6979533B2 (en) | 1992-06-12 | 2005-12-27 | The Trustees Of The University Of Pennsylvania | Determination of endometrial receptivity toward embryo implantation |
| CA2203718A1 (en) | 1997-04-25 | 1998-10-25 | University Of British Columbia | Cadherin-11 as an indicator of viable pregnancy |
| IL127896A0 (en) | 1998-12-31 | 1999-10-28 | Gail Laster | A novel treatment for preeclampsia and related diseases |
| WO2001066786A1 (en) | 2000-03-08 | 2001-09-13 | Kliman Harvey J | Methods of diagnosing and monitoring endometrial glandular development |
| AU2001264900A1 (en) | 2000-05-24 | 2001-12-03 | Schering Aktiengesellschaft | Pharmaceutical use of fibulin-1 |
| US6780594B2 (en) | 2000-09-25 | 2004-08-24 | Schering Aktiengesellschaft | Method for in vitro diagnosis of endometriosis |
| AUPR673001A0 (en) | 2001-07-31 | 2001-08-23 | Prince Henry's Institute Of Medical Research | Pregnancy-related enzyme activity |
| DE10139874A1 (de) | 2001-08-10 | 2003-04-30 | Schering Ag | Humane Mater-Proteine |
| GB0201284D0 (en) | 2002-01-21 | 2002-03-06 | Isis Innovation | Screening methods for contraceptive and fertility agents |
| US20030186300A1 (en) | 2002-03-20 | 2003-10-02 | Ali Akoum | Methods and products for modulation of reproductive processes and for diagnosis, prognostication and treatment of related conditions |
| CA2489568A1 (en) | 2002-05-14 | 2004-07-22 | The Board Of Trustees Of The Leland Stanford Junior University | Endometrial genes in endometrial disorders |
| DE10236405A1 (de) | 2002-08-02 | 2004-02-19 | Schering Ag | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper Aktivität für die weibliche Fertilitätskontrolle und Hormonersatztherapie |
| AU2003255355A1 (en) | 2002-08-02 | 2004-02-25 | Schering Aktiengesellschaft | Progesterone receptor modulators having an increased antigonadotropic activity for use in female fertility testing and hormone replacement therapy |
| DE10361928A1 (de) | 2002-12-21 | 2004-07-01 | Universität Leipzig | Verfahren und Mittel zur Bestimmung von bestimmten Zuständen bzw. Veränderungen im Uterusepithel und im Epithel anderer Organe |
| WO2005018796A1 (en) | 2003-08-21 | 2005-03-03 | Pamgene B.V. | Microarray support for bioprobe synthesis |
| CN1863905A (zh) | 2003-09-08 | 2006-11-15 | 得克萨斯系统大学董事会 | 通过用前列腺素或前列腺素类似物补充培养基加强体外胚发育的方法以及组合物 |
| WO2005026324A2 (en) | 2003-09-08 | 2005-03-24 | The Board Of Regents Of The University Of Texas System | Method and composition for enhancing in vitro embryo development by supplementing culture medium with prostaglandin or a prostaglandin analog |
| EP2251695B1 (en) | 2003-12-23 | 2013-07-17 | Mount Sinai Hospital Corporation | Markers associated with endometrial disease |
| EP1765083A4 (en) | 2004-05-28 | 2008-08-20 | Serono Lab | USE OF IL-17 TO TREAT FERTILITY DISORDERS |
| US20090111140A1 (en) * | 2006-03-31 | 2009-04-30 | Koninklijke Philips Electronics N.V. | Systems and methods for cell measurement utilizing ultrashort t2* |
| JP2007278750A (ja) | 2006-04-04 | 2007-10-25 | Ono Pharmaceut Co Ltd | プロスタグランジン類及びその類縁体の定量方法 |
| WO2008036374A2 (en) * | 2006-09-21 | 2008-03-27 | Medistem Laboratories, Inc. | Allogeneic stem cell transplants in non-conditioned recipients |
| GB0703683D0 (en) * | 2007-02-26 | 2007-04-04 | Ark Therapeutics Ltd | The treatment of complications in pregnancy |
| US9259233B2 (en) * | 2007-04-06 | 2016-02-16 | Hologic, Inc. | Method and device for distending a gynecological cavity |
| US8673850B2 (en) | 2008-05-30 | 2014-03-18 | Institut De Recherches Cliniques De Montreal | PCSK9 inhibitors and methods of use thereof |
| WO2010010201A1 (es) | 2008-07-22 | 2010-01-28 | Equipo Ivi Investigacion Sl | Perfil de expresion genetica como marcador de la receptividad endometrial |
| WO2013166281A1 (en) * | 2012-05-02 | 2013-11-07 | Cedars-Sinai Medical Center | Bi-functional compositions for targeting cells to diseased tissues and methods of using same |
| EP2348318A1 (en) | 2010-01-21 | 2011-07-27 | Equipo Ivi Investigación, S.L. | Diagnostic method for endometrial receptivity |
| ES2662571T3 (es) | 2011-10-21 | 2018-04-09 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Métodos de evaluación de la receptividad endometrial de una paciente tras una hiperestimulación ovárica controlada |
| CN104053668B (zh) | 2011-11-30 | 2020-09-11 | 新加坡科技研究局 | 用于生物学检测的gm1神经节苷脂与膜联蛋白v的微粒多肽比例 |
| ES2681238T3 (es) | 2012-06-27 | 2018-09-12 | F. Hoffmann-La Roche Ag | Medios y métodos de aplicación de la relación sFlt-1/PIGF o Endoglina/PIGF para descartar la aparición de preeclampsia en un cierto periodo de tiempo |
| RU2515475C1 (ru) * | 2012-11-15 | 2014-05-10 | Федеральное государственное бюджетное учреждение науки ИНСТИТУТ ЦИТОЛОГИИ РОССИЙСКОЙ АКАДЕМИИ НАУК | Способ стимуляции образования децидуальной оболочки эндометрия в эксперименте |
| BR112016021630A2 (pt) | 2014-03-21 | 2020-02-27 | Igenomix, S.L. | Composição para tratar pré-eclampsia, método de uso do nível de anexina a2 (anxa2) como indicador de pré-eclampsia e método para avaliar a eficácia da terapia de glicosaminoglicano para pré-eclampsia |
| CA2952559C (en) | 2014-06-17 | 2023-01-24 | Igenomix S.L. | Stem cell therapy in endometrial pathologies |
-
2015
- 2015-06-05 CA CA2952559A patent/CA2952559C/en active Active
- 2015-06-05 EP EP15781411.2A patent/EP3158057B1/en active Active
- 2015-06-05 SI SI201530822T patent/SI3158057T1/sl unknown
- 2015-06-05 HR HRP20220419TT patent/HRP20220419T1/hr unknown
- 2015-06-05 HU HUE15781411 patent/HUE044823T2/hu unknown
- 2015-06-05 SI SI201531822T patent/SI3569697T1/sl unknown
- 2015-06-05 TR TR2019/10410T patent/TR201910410T4/tr unknown
- 2015-06-05 RS RS20240690A patent/RS65719B1/sr unknown
- 2015-06-05 AU AU2015275798A patent/AU2015275798B2/en active Active
- 2015-06-05 PL PL22150013.5T patent/PL4012023T3/pl unknown
- 2015-06-05 US US15/318,825 patent/US11129851B2/en active Active
- 2015-06-05 SM SM20190400T patent/SMT201900400T1/it unknown
- 2015-06-05 RS RSP20190913 patent/RS59210B1/sr unknown
- 2015-06-05 DK DK15781411.2T patent/DK3158057T3/da active
- 2015-06-05 EP EP19169309.2A patent/EP3569697B8/en active Active
- 2015-06-05 PT PT191693092T patent/PT3569697T/pt unknown
- 2015-06-05 PL PL19169309T patent/PL3569697T3/pl unknown
- 2015-06-05 BR BR112016029558A patent/BR112016029558A2/pt not_active Application Discontinuation
- 2015-06-05 PT PT15781411T patent/PT3158057T/pt unknown
- 2015-06-05 SM SM20240270T patent/SMT202400270T1/it unknown
- 2015-06-05 HR HRP20240798TT patent/HRP20240798T1/hr unknown
- 2015-06-05 ES ES22150013T patent/ES2983444T3/es active Active
- 2015-06-05 HU HUE19169309A patent/HUE058328T2/hu unknown
- 2015-06-05 WO PCT/IB2015/001715 patent/WO2015193737A1/en not_active Ceased
- 2015-06-05 SM SM20220155T patent/SMT202200155T1/it unknown
- 2015-06-05 PL PL15781411T patent/PL3158057T3/pl unknown
- 2015-06-05 HR HRP20191240 patent/HRP20191240T1/hr unknown
- 2015-06-05 CN CN201580043147.1A patent/CN107073040A/zh active Pending
- 2015-06-05 RS RS20220339A patent/RS63093B1/sr unknown
- 2015-06-05 MX MX2016016756A patent/MX377300B/es active IP Right Grant
- 2015-06-05 RU RU2017101147A patent/RU2725006C2/ru active
- 2015-06-05 LT LTEP15781411.2T patent/LT3158057T/lt unknown
- 2015-06-05 ES ES15781411T patent/ES2736117T3/es active Active
- 2015-06-05 LT LTEP19169309.2T patent/LT3569697T/lt unknown
- 2015-06-05 JP JP2016573587A patent/JP6920062B2/ja active Active
- 2015-06-05 ES ES19169309T patent/ES2910306T3/es active Active
- 2015-06-05 HU HUE22150013A patent/HUE067463T2/hu unknown
- 2015-06-05 CN CN202310575540.1A patent/CN116747241A/zh active Pending
- 2015-06-05 EP EP22150013.5A patent/EP4012023B1/en active Active
- 2015-06-05 DK DK19169309.2T patent/DK3569697T3/da active
-
2019
- 2019-07-16 CY CY20191100753T patent/CY1122615T1/el unknown
-
2020
- 2020-06-12 JP JP2020102340A patent/JP2020138984A/ja active Pending
-
2022
- 2022-04-05 CY CY20221100258T patent/CY1125938T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2983444T3 (es) | Tratamiento de células madre en patologías endometriales | |
| Gao et al. | Uterine artery embolization followed by dilation and curettage within 24 hours compared with systemic methotrexate for cesarean scar pregnancy | |
| Zhang et al. | Using 17β‐estradiol heparin‐poloxamer thermosensitive hydrogel to enhance the endometrial regeneration and functional recovery of intrauterine adhesions in a rat model | |
| Puente Gonzalo et al. | Intrauterine infusion of platelet-rich plasma for severe Asherman syndrome: a cutting-edge approach | |
| ES2767182T3 (es) | Células madre pluripotentes que inducen reparación y regeneración después de un infarto de miocardio | |
| Hu et al. | Cyclical endometrial repair and regeneration: Molecular mechanisms, diseases, and therapeutic interventions | |
| JP2016540014A (ja) | 幹細胞由来のエキソソームを有効成分に含む脳血管疾患治療用薬学的組成物 | |
| Fan et al. | Umbilical cord mesenchyme stem cell local intramuscular injection for treatment of uterine niche: Protocol for a prospective, randomized, double-blinded, placebo-controlled clinical trial | |
| ES2910115T3 (es) | Células madre mesenquimales preacondicionadas con trombina para el tratamiento de la EIH neonatal | |
| US11931383B2 (en) | Bioactive renal cells for the treatment of chronic kidney disease | |
| de Miguel‐Gómez et al. | Strategies for managing Asherman's syndrome and endometrial atrophy: since the classical experimental models to the new bioengineering approach | |
| Santamaria et al. | Should we consider alternative therapies to operative hysteroscopy for the treatment of Asherman syndrome? | |
| Stępniak et al. | Effectiveness, complications and reproductive outcome of selective chemoembolization with methotrexate followed by suction curettage for caesarean scar pregnancy-A prospective observational study | |
| HK40075844A (en) | Stem cell therapy in endometrial pathologies | |
| HK40075844B (en) | Stem cell therapy in endometrial pathologies | |
| HK1242600A1 (en) | Stem cell therapy in endometrial pathologies | |
| Delis | AMD3100 Administration for the Treatment of Asherman’s Syndrome in a Murine Model | |
| de Miguel Gómez et al. | Stem Cell Transplantation for Endometrial Regeneration in Humans | |
| Santamaria et al. | Hysteroscopy and Stem Cell Therapy to Approach Refractory Asherman’s Syndrome | |
| Maegawa et al. | A case of placental polyp treated with an intraoperative injection of prostaglandin F2α followed by hysteroscopic resection | |
| Seifer et al. | Stem cell therapies for atrophic endometrium and Asherman's syndrome | |
| Patel et al. | Birth of a healthy infant after bone marrow-derived cell therapy Alternative title (right-running-head): Birth of a healthy infant after bone marrow-derived cell concentrate T | |
| Nosheen | Histopathological Findings of Abdominal Hysterectomies in Patients Presenting with Heavy Menstrual Bleeding (HMB) | |
| Delling et al. | CT-1330 Accepted 11/20/2014 for publication in “Cell Transplantation” In vivo tracking and fate of intraarticularly injected superparamagnetic iron oxide particle-labeled multipotent stromal cells in an ovine model of osteoarthritis |